Drug Name:
BOOSTRIX Rx
Generic Name and Formulations:
Tetanus and reduced diphtheria toxoid, acellular pertussis vaccine (aluminum hydroxide adsorbed); susp for IM inj; preservative-free.
Company:
GlaxoSmithKline
Therapeutic Use:
Indications for BOOSTRIX:
Diphtheria, tetanus, and pertussis booster immunization in patients ≥10 years of age.
Adults and Children:
<10yrs: not recommended. ≥10yrs (≥5yrs after last childhood DTwP or DTaP or adult Td vaccine): 0.5mL IM once into deltoid muscle.
Contraindications:
Encephalopathy within 7 days after previous DTaP or DTwP vaccination.
Warnings/Precautions:
Guillain-Barre syndrome (within 6 weeks) after previous tetanus toxoid vaccine: see literature. Progressive or unstable neurologic disorders (eg, cerebrovascular events, acute encephalopathic conditions). Previous Arthus-type hypersensitivity reaction: not recommended until ≥10yrs after prior dose of tetanus toxoid-containing vaccine. Immunosuppressed. Have epinephrine available. Latex allergy. Pregnancy (Cat.C). Nursing mothers.
Pharmacological Class:
Tdap.
Interactions:
Concomitant vaccines: see literature. Immunosuppressants (eg, radiation, chemotherapy, high-dose steroids): may get suboptimal response.
Adverse Reactions:
Local reactions (eg, pain), fever, headache, fatigue, GI upset.
Note:
Register pregnant patients exposed to Boostrix by calling (888) 452-9622. Report adverse events to VAERS by calling (800) 822-7967.
How Supplied:
Vials (single dose)—10; Prefilled syringes (without needles)—1, 5, 10
Sign Up for Free e-newsletters
ONA Articles
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- NIH Establishes Educational Program on Genomics, Genetics for Oncology Nurses
- Some Obesity-Related Cancers Increasing in Younger Adults
- Less Diversity in PROM Systems Could Improve Assessing Their Practicality for Cancer Patients, Clinicians
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Shifting Dynamics of Social Support After a Cancer Diagnosis
- Nurse-Led vs Oncologist-Led Breast Cancer Follow-up Program: Early Feasibility Results of an Ongoing Study
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |